紫杉醇涂层球囊治疗CLTI与非CLTI患者5年预后比较:BIOLUX P-III注册研究
BIOLUX P-III注册研究预设亚组分析,纳入877例接受Passeo-18 Lux紫杉醇涂层球囊治疗的下肢动脉疾病患者,比较328例CLTI患者与非CLTI患者60个月预后。两组靶病变血运重建率和主要不良事件发生率相似,但CLTI患者5年生存率(47.9% vs 76.7%)和无截肢生存率(47.1% vs 75.7%)显著更低。
要点
- CLTI患者5年生存率47.9%,显著低于非CLTI患者的76.7%。
- CLTI患者5年无大截肢率93.3%,低于非CLTI的99.3%。
- 两组靶病变血运重建率和主要不良事件发生率无显著差异。
核心结论
- Passeo-18 Lux治疗5年内病变层面耐久性得以保持,但CLTI代表高危预后表型,生存和肢体结局较差。
- CLTI长期结局受全身合并症、早期肢体脆弱性、竞争性死亡和伤口相关因素影响,而非仅器械性能。
研究设计与样本
- BIOLUX P-III为前瞻性国际上市后全纳入注册研究,评估Passeo-18 Lux紫杉醇涂层球囊治疗下肢动脉疾病。
- 预设亚组分析比较CLTI与非CLTI患者60个月结局,共877例治疗患者,其中328例(37.4%)为CLTI。
- 采用Kaplan-Meier法分析时间-事件结局,因60个月随访完整性下降,晚期估计需考虑删失、脱落和竞争性死亡。
主要发现
- 两组技术成功率均超过98%,CLTI患者基线合并症更多、肢体威胁更晚期、膝下病变更常见。
- 60个月无临床驱动靶病变血运重建率CLTI组85.3% vs 非CLTI组78.3%(P=.59),无主要不良事件率76.5% vs 74.3%(P=.13)。
- 5年生存率CLTI组47.9% vs 非CLTI组76.7%(P<.001),无大截肢率93.3% vs 99.3%(P<.001),无截肢生存率47.1% vs 75.7%(P<.001)。
- CLTI患者尽管死亡率更高,但接受的累积紫杉醇剂量更低。
关键数值与推荐
- CLTI组60个月无临床驱动靶病变血运重建率85.3%,非CLTI组78.3%(P=.59)。
- CLTI组60个月无主要不良事件率76.5%,非CLTI组74.3%(P=.13)。
- CLTI组5年生存率47.9%,非CLTI组76.7%(P<.001)。
- CLTI组5年无大截肢率93.3%,非CLTI组99.3%(P<.001)。
- CLTI组5年无截肢生存率47.1%,非CLTI组75.7%(P<.001)。
临床怎么用
- CLTI应被视为高危临床表型,需综合心血管风险降低、多学科管理和结构化术后监测。
- 长期结局受全身合并症、竞争性死亡和伤口因素影响,患者咨询和治疗决策需个体化。
- 药物涂层球囊在CLTI患者中病变层面耐久性保持,但需关注肢体和生存结局。
局限性
- 60个月随访完整性显著下降,晚期估计需在删失、脱落和竞争性死亡背景下解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic limb-threatening ischaemia (CLTI) carries a high risk of death, limb loss, and impaired functional recovery despite revascularisation. Drug-coated balloons may reduce restenosis and repeat intervention after infrainguinal endovascular therapy, but long-term safety and effectiveness data in patients with CLTI remain limited. METHODS: We performed a prespecified subgroup analysis of BIOLUX P-III, a prospective international post-market all-comers registry evaluating the Passeo-18 Lux paclitaxel-coated balloon for infrainguinal peripheral artery disease. Outcomes were compared between patients with and without CLTI through 60 months. Endpoints included freedom from major adverse events, clinically driven target-lesion revascularisation, major target-limb amputation, amputation-free survival and all-cause mortality. Time-to-event outcomes were analysed using Kaplan-Meier methods. Because follow-up completeness declined substantially by 60 months, late estimates were interpreted in the context of censoring, attrition and competing mortality. RESULTS: Among 877 treated patients, 328 (37.4%) had CLTI. Technical success exceeded 98% in both groups. Patients with CLTI had greater baseline comorbidity, more advanced limb threat and more frequent below-the-knee disease. At 60 months, freedom from clinically driven target-lesion revascularisation was 85.3% in patients with CLTI and 78.3% in those without CLTI (P = .59), and freedom from major adverse events was similar (76.5% vs 74.3%; P = .13). In contrast, 5-year survival was substantially lower in patients with CLTI (47.9% vs 76.7%; P < .001). Freedom from major target-limb amputation was lower (93.3% vs 99.3%; P < .001), and amputation-free survival was reduced (47.1% vs 75.7%; P < .001). Patients with CLTI received a lower cumulative paclitaxel dose despite higher mortality. CONCLUSIONS: Passeo-18 Lux treatment was associated with preserved lesion-level durability through 5 years, but CLTI identified a high-risk prognostic phenotype with poor survival and limb outcomes. These findings suggest that long-term outcomes in CLTI are influenced by systemic comorbidity, early limb vulnerability, competing mortality and wound-related factors beyond lesion-level device performance alone.Clinical ImpactThis study provides clinically relevant insights into the long-term outcomes of patients with chronic limb-threatening ischaemia (CLTI) undergoing endovascular revascularisation with drug-coated balloons. Despite high procedural success, patients with CLTI experience substantially greater long-term mortality and adverse limb outcomes than those with intermittent claudication. These findings highlight the importance of recognising CLTI as a high-risk clinical phenotype requiring comprehensive cardiovascular risk reduction, multidisciplinary management, and structured postprocedural surveillance. The study's principal contribution is its evaluation of five-year outcomes in a real-world, all-comers population, providing valuable evidence to inform patient counselling, individualised treatment strategies, and long-term clinical decision-making.
引用
- Dodd J, Brodmann M, Wang JCC, et al. Five-Year Prognostic Outcomes After Paclitaxel-Coated Balloon Treatment According to Chronic Limb-Threatening Ischaemia Status: Insights From the BIOLUX P-III Registry. J Endovasc Ther. 2026. PMID: 42961070. doi:10.1177/15266028261495344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。